ArticleNeurology2021
COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology.
Article in Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Is there still hesitancy towards SARS-CoV-2 vaccination among people with neurological disease- a survey of the NeuroCOVID-19 task force of the European Academy of Neurology.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Adverse Events of COVID-19 Vaccines in the United States: Temporal and Spatial Analysis.JMIR public health and surveillance · 2024Article
- Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: A systematic review and meta-analysis.Heliyon · 2024Article
- Article
- Evaluation of serum and cerebrospinal fluid biomarkers after vaccination against SARS-CoV-2.Annals of clinical and translational neurology · 2023Article
- Increasing Use of Telemedicine for Neurological Disorders During the COVID-19 Pandemic: A Mini-Review.Journal of multidisciplinary healthcare · 2023Review
- COVID-19 in children and adolescents with neuroimmunological disorders.Clinics (Sao Paulo, Brazil) · 2023Article
- Reversible neurological and brain MRI changes following COVID-19 vaccination: A case report.Journal of neuroradiology = Journal de neuroradiologie · 2022Article
- Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity.Multiple sclerosis and related disorders · 2022Review
- Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study.Brain sciences · 2022Article
- Postvaccinal GABA-B receptor antibody encephalitis after ChAdOx1 nCoV-19 vaccination.Annals of clinical and translational neurology · 2022Article
- Review
- The COVID-19 pandemic, an environmental neurology perspective.Revue neurologique · 2022Review
- Neurological consequences of COVID-19 and brain related pathogenic mechanisms: A new challenge for neuroscience.Brain, behavior, & immunity - health · 2022Review
- The relationship between myasthenia gravis and COVID-19: a systematic review.The Egyptian journal of neurology, psychiatry and neurosurgery · 2022Review
- Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data.Multiple sclerosis and related disorders · 2022Observational
- Ayurvedic management of neurological deficits post COVID-19 vaccination - A report of two cases.Journal of Ayurveda and integrative medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic caused by the SARS-CoV-2 virus has left many unanswered questions for patients with neurological disorders and the providers caring for them. Elderly and immunocompromised patients are at increased risk for severe symptoms due to COVID-19, and the virus may increase symptoms of underlying neurological illness, particularly for those with significant bulbar and respiratory weakness or other neurologic disability. Emerging SARS-CoV-2 vaccines offer substantial protection from symptomatic infection, but both patients and providers may have concerns regarding theoretical risks of vaccination, including vaccine safety and efficacy in the context of immunotherapy and the potential for precipitating or exacerbating neurological symptoms. In this statement on behalf of the Quality Committee of the AAN we review the current literature, focusing on COVID-19 infection in adults with neurological disease, in order to elucidate risks and benefits of vaccination in these individuals. Based on existing evidence, neurologists should recommend COVID-19 vaccination to their patients. For those patients being treated with immunotherapies, attention should be paid to timing of vaccination with respect to treatment and the potential for an attenuated immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.